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Background: We report a case of progressive Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) with
life-threatening complications of both the underlying disease and induction immunosuppressive therapy. Here, for the
first time, cyclophosphamide toxicity and severe opportunistic infections including pneumocystis jirovecii- pneumonia
were found in one case in a close temporal relationship.
Case presentation: A 34-year-old male patient of Caucasian ethnicity presented with acute renal failure
necessitating hemodialysis treatment due to Granulomatosis with Polyangiitis (Wegener’s Granulomatosis).
Kidney disease progressed to end-stage renal disease shortly after first diagnosis. After the 2nd bolus of
cyclophosphamide shortly, induction immunosuppression (glucocorticoid/cyclophosphamide) was interrupted
for repeat infections and resumed 5 years later. By that time, the lungs developed large pulmonary cavernae
most likely due to smoldering granuloma indicative for the failed goal of disease remission. Therefore, induction
immunosuppression was resumed. Following two monthly boli of cyclophosphamide, the patient developed
pericardial effusion and, consecutively, atrioventricular blockade most likely due to cyclophosphamide. After
recovery, the patient was discharged without cotrimoxacole. 10 weeks after the last cyclophosphamide bolus
and 6 weeks after cessation of cotrimoxacole, the patient was readmitted to the intensive-care unit with
Pneumocystis jirovecii pneumonia, and died 6 months later or 74 months after first diagnosis of Granulomatosis
with Polyangiitis.
Conclusions: This case illustrates both the need for adequate immunosuppressive therapy to reach disease
remission and the limitations thereof in terms of complications including cardiotoxicity of cyclophosphamide and
Pneumocystis jirovecii pneumonia. In line with current recommendations, the present case strongly encourages
pneumocystis jirovecii- pneumonia chemoprophylaxis for at least 6 months following induction therapy in
Granulomatosis with Polyangiitis.
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Granulomatosis with polyangiitis (GPA), formerly called
Wegener’s Granulomatosis, generally presents with pul-
monary and renal failure due to vasculitis caused by anti-
neutrophil cytoplasmic antibodies directed against cytosolic
proteinase-3 (cANCA). In addition, granuloma formation
of the lungs and upper airways may lead to hemoptysis and
lung destruction. Less frequently, GPA-associated granu-
loma occur in the skin, eye, joints, gastrointestinal tract or
heart [1-5]. Elevated serum cANCA, clinical clues and/or
typical histological findings of kidney biopsies establish the
diagnosis of GPA. Cyclophosphamide or monoclonal anti-
CD20 antibody (rituximab) therapy is employed as induc-
tion immunosuppression to achieve disease remission.
Nevertheless, despite optimal induction and maintenance
immunosuppression, GPA relapses in about 50% of all cases
within five years after first diagnosis, translating into a
poorer prognosis [6].
Immunosuppressive therapy renders GPA patients sus-
ceptible to life-threatening opportunistic infections such as
pneumocystis jirovecii pneumonia (PCP). Current recom-
mendations encourage the use of co-trimoxazole as PCP
chemoprophylaxis following induction therapy [7,8] as well
as in maintenance therapy in GPA [9,10]. Acceptance rate
of this recommendation still needs to be improved [11,12].
Here, we report a case of progressive GPA complicated by
cyclophosphamide cardiotoxicity and infections including
PCP.
Case presentation
A 34 year-old male patient of Caucasian ethnicity was diag-
nosed with a 3rd degree acute kidney injury (Acute Kidney
Injury Network classification [13]) in a regional German
hospital. Co-morbidities included arterial hypertension,
obstructive sleep apnea, obesity (body-mass index: 40.4
kg/m2), tobacco abuse, and chronic obstructive pulmonary
disease (COPD). Based on an elevated serum cANCA titer,
the diagnosis of GPA was established. A histological con-
firmation was obtained by kidney biopsy. Initially, seven
sessions of plasmapheresis and induction immunosup-
pression (500 mg i.v. methylprednisolone for 3 days, ster-
oid taper-off, 0.5 g cyclophosphamide i.v. twice within two
months) were applied leading to a partial remission of
GPA. However, a bronchoscopy-proven mycotic pneumo-
nia (aspergillus fumigatus) occurred following the second
bolus of cyclophosphamide requiring antimycotic treatment
(voriconacole 200 mg bid) for several months. Immunsup-
pressive induction therapy was stopped immediately.
Hence, due to the halted immunosuppressive therapy, kid-
ney function progressively deteriorated. Eleven months
after onset of GPA, the patient had to be hospitalized for
hemodialysis-access surgery and hemodialysis initiation.
During the following 4 years, hemodialysis-fistula throm-
bosis and repeat catheter-associated bloodstream infections,episodes of exacerbated COPD and pneumonia occurred.
The patient ignored recommendations regarding fluid in-
take. Because of respiratory symptoms related to overhydra-
tion and infections, the patient was deemed unfit to
proceed with cyclophosphamide induction. A maintenance
therapy with prednisolone (10 mg) was prescribed. Four
years after GPA diagnosis, CRP and cANCA serum levels
rose, and the patient had to be hospitalized three times
within a year due to progressive dyspnea, cough and fever.
During the last hospitalization one year before index
hospitalization, bronchoscopy ruled out opportunistic in-
fections. Mycophenolate mofetil was introduced as new
maintenance immunosuppression for suspected smoldering
disease activity in the lungs. Five years after first diagnosis
of GPA, the patient received the third and forth intravenous
bolus of cyclophosphamide (0.6 g each) within two months.
Voriconacole (200 mg twice daily) and co-trimoxazole (960
mg/d) were added as prophylaxis for mycotic pneumonia
and PCP. Within less than 24 hours following the 4th cyclo-
phosphamide bolus given after hemodialysis, the patient de-
veloped dyspnea at rest necessitating re-hospitalisation,
endotracheal intubation and assisted mechanical ventila-
tion. Echocardiography showed a pericardial effusion (end-
diastolic: 2.5 cm), massive right-ventricular dilation and
hypokinesia. New ECG changes triggered an immediate
coronary angiography exam which excluded clogged coron-
aries. Right-ventricular catheterization showed an elevated
pulmonary-artery pressure: 74/54/58 mmHg (systolic/dia-
stolic/mean). There, pulmonary-artery embolism was
excluded. Cardiac enzymes remained unrevealing. The peri-
cardial effusion disappeared after one month. As another
sign of cyclophosphamide toxicity, anemia and neutropenia
occurred. Anemia had to be corrected by two packed
erythrocyte concentrates. Neutropenia was complicated by
sepsis with elevated procalcitonin (PCT: 13.6 ng/ml) and C-
reactive protein (CRP: 259 mg/l) one week after the 4th
bolus of cyclophosphamide. The patient was again on
assisted mechanical ventilation for 11 days. Thoracic com-
puted tomography showed pulmonary infiltrates within
large, partly calcified pulmonary cavernae (maximum 6 cm
in diameter). Under intensified antibiosis guided by micro-
biologic findings from bronchoalveolar lavage, the sepsis
subsided. Coincidentally, either GPA disease activity or late
sequelae of cyclophosphamide, the patient had to be reani-
mated for third-degree atrioventricular block two weeks
after the 4th bolus of cyclophosphamide. The latter possibil-
ity appears to be more likely because cytoplasmic ANCA
titer only was 1:20 seven days before. A permanent pace-
maker was inserted, and the patient was discharged with p.
o. antibiosis, p.o. prednisolone (10 mg/d), however, without
voriconacole or co-trimoxazole three weeks after admis-
sion. Six weeks following discharge or 10 weeks after the
fourth cyclophosphamide bolus, the patient was readmitted
for suspected pneumogenic sepsis with worsening dyspnea
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transferred to an intensive-care unit (ICU) requiring cat-
echolamine therapy and mechanical ventilation for five
days. Blood cultures remained negative. Sputum revealed
Pneumocystis jirovecii, Candida albicans, Peptostreptococ-
cus micros, and Actinomyces israelii. Tuberculosis was
ruled out using blood test and in culture of bronchoalveo-
lar fluid following bronchoscopy. Both Cytomegalovirus
(CMV) IgM and IgG were positive. However, weekly
CMV PCR of serum samples remained negative. Both T-
helper lymphocyte count (242/μl) and plasma immuno-
globulin G level (6.4 g/l) were low indicative for a state of
over-immunosuppression.
In addition, a GPA relapse was suspected based on an el-
evated cANCA concentration (129.9 U/ml). Thoracic com-
puted tomography showed the known pulmonary cavernae
and new pulmonary opacities consistent with PCP or GPA-
associated vasculitis (Figure 1). Lung-function tests revealed
an impaired vital capacity (2.08 l or 54% of reference value),
ruled out obstruction (Tiffenau test: 77.7% of maximum
vital capacity or 103% of reference value). Intravenous i.v.
co-trimoxazole therapy (1 × 1920 mg i.v. for 2 days, 3 ×
1920 mg dissolved in 500 ml saline for 12 days) was applied
in addition to i.v. antibiosis (imipenem-cilastatin for 14 d)
and immunosuppression (prednisolone 50 mg/d). For
the suspected recurrent GPA, daily plasmapheresis was
conducted over 5 days since admission with 3 liter or
70% of estimated patient’s plasma volume of 5% human-
albumin solution. Under daily hemodialysis, the patient’s
condition improved, cANCA concentration decreased (29.3
U/ml), serum inflammatory parameters partly normalized
(Figure 2). Following discharge (38 days after admission),
peroral co-trimoxazole (960 mg/d) and prednisolone (40
mg/d) were maintained. Two weeks later, the patient was
readmitted for suspected pneumonia. Laboratory testsPneumocystis jirovecii Pneumo
Figure 1 Representative thoracic computed tomography scan at the timrevealed an increased CRP (206 mg/l), PCT (2 ng/ml) and
cANCA concentration (54.9 U/ml). Computed tomography
of the chest was consistent with bronchitis, ruled out
pneumonia. Bronchoscopy-guided peroral antibiosis with
moxifloxacin (400 mg/d) was initiated, and maintenance
immunosuppression (azathioprin 75 mg/d, prednisolone
25 mg/d) was increased for a suspected GPA relapse.
However, two months later, azathioprin had to be discon-
tinued, and prednisolone was reduced (10 mg/d) due to
an aggravated respiratory infection (CRP 121 mg/l). Body
weight (95 kg) was found to be decreased by 33 kg or by
25% since PCP onset. Despite antibiosis, a pneumogenic
sepsis occurred. The patient was admitted to an ICU
admission, received mechanical ventilation and extra-
corporal carbon dioxyde elimination. Intravenous anti-
biosis was adjusted to bronchoalveolar-lavage results.
During the 5-months stay at the ICU, a non-ST segment
elevation myocardial infarction occurred requiring a per-
cutanous coronary intervention. Shortly thereafter, an
intracranial bleeding under anticoagulation with epileptic
convulsion, a biopsy-proven cytomegalovirus colitis and
viral pneumonitis (H1N1 influenza) complicated the
course of disease. Despite several switches of antimicrobial
and antiviral therapy, the patient died 74 months after
GPA onset.
Conclusions
This case of GPA illustrates the narrow path between
therapeutic control of GPA activity and opportunistic in-
fections or complications due to medical immunosuppres-
sion. The overall goal is disease remission without
infectious complications or side effects. To reach this goal,
various variables including age, renal and liver function
need to be considered on an individual basis. Most im-
portantly, a concomitant infection needs to be ruled outnia and GPA-related cavernae
e of hospitalisation for Pneumocystis jirovecii pneumonia (PCP).




























































*Sputum: Pneumocystis jirovecii,Candida albicans, Peptostreptococcus miros, Actinomyces israelii, 
**Bronchoscopy: Haemophilus parainfluencae, Neisseria species, Streptococcus viridans group
***Bronchoskopy: Enterococcus faecium, Blood: Staphylococcus epidermidis
Figure 2 Time course of C-reactive protein (CRP), procalcitonin (PCT) and anti-neutrophil cytoplasmic antibodies directed against
cytosolic proteinase-3 (cANCA) during opportunistic infections (elevated CRP and PCT) and suspected relapses (elevated CRP and
cANCA). The time of hospitalisation is indicated. In addition, relevant microbiologic results were provided.
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plasma-exchange therapy may be the initial modality of
choice to restore kidney function [14] given its rapid action
to reduce antibody load and its moderate immunosuppres-
sive action, especially when the exchange medium used is
human plasma.
Here, PCP occurred 8 weeks following cessation of
PCP chemoprophylaxis or 10 weeks after the last bolus
of cyclophosphamide. From this case, the role for PCP
chemoprophylaxis in GPA after induction immunosup-
pression is emphasized. It is tempting to speculate that
an ongoing PCP chemoprophylaxis would have avoided
or greatly diminished the risk for PCP in this patient.
Clearly, the current practice on PCP chemoprophylaxis in
vasculitis such as GPA should be streamlined by guide-
lines [15] which has been done so far by the European
League Against Rheumatism [16]. There, co-trimoxacole
(800/160 mg on alternate days or 400/80 mg daily) is rec-
ommended. In analogy to kidney transplant recipients
[17,18], the time of prophylaxis should cover 6 months
after induction immunosuppression in GPA. In addition,
PCP chemoprophylaxis may be considered, if cellular im-
munity is found to be greatly attenuated as indicated by a
reduced total lymphocyte count [19], a reduced T-helper
lymphocyte count (<400/μl) or the presence of end-stage
renal disease [20]. Besides its role in PCP prophylaxis, co-
trimoxazole (800/160 mg twice daily) may be consideredas an adjunct to standard maintenance therapy with re-
gard to risk reduction of GPA relapse.
Regarding the underlying disease, neither the initial two
cyclophosphamide boli nor the third and fourth one five
years later led to complete remission of GPA. Shortly after
GPA diagnosis, immunosuppressive induction therapy was
withheld due to infections. Meanwhile, GPA progressed to
end-stage-renal disease and caused massive pulmonary de-
fects that, in turn, became persistent infectious foci. Clearly,
disease remission is a prerequisite for an acceptable long-
term outcome in GPA, even in the case when end-stage
renal disease has been reached. The presence of end-stage
renal disease was not shown to slow down GPA progres-
sion or prevent relapses of GPA [21]. Besides the need for
disease remission, the continued tobacco abuse and the in-
compliant drinking behaviour leading to over-hydration
may have favoured infectious complications in this case as
well.
Clinically, infections may have obscured GPA symp-
toms. To differentiate between infection and GPA pro-
gression, regular radiological and laboratory assessments
are mandatory. Radiological signs and laboratory parame-
ters including CRP and cANCA may raise suspicion for
GPA progression. In addition, as an indirect proof, a set
plasmapheresis sessions may help differentiate between
GPA progression (responder of plasma exchange) and in-
fection (elevated PCT). Here, plasmapheresis improved
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during hospitalisation for PCP indicating that GPA pro-
gression concurrently occurred.
Side effects of immunosuppressive therapy for GPA
are another concern. The timely relationship between
cyclophosphamide therapy and the occurrence of acute
right-heart failure and pericardial effusion suggested
cyclophosphamide cardiotoxicity in analogy to previous
reports [22-24]. Cyclophosphamide toxicity concerns
arise in all patients with renal dysfunction even though
the cyclophosphamide dose was relatively low (600 mg)
in the present case. To safeguard for toxicity, the timing
of hemodialysis (12 hours after cyclophosphamide ex-
posure) is pertinent [25]. This requirement was not ful-
filled here.
In summary, this case underlines the importance of
disease remission in GPA, and supports the concept of
PCP chemoprophylaxis with co-trimoxazole for up to 6
months after intensified medical immunosuppression.
Co-trimoxazole as adjunct to maintenance therapy in
GPA would serve both as life-long PCP prophylaxis and
remission control [26,27]. In addition, the role of novel
vasculitis activity markers such as circulating endothe-
lial cells and endothelial microparticles [28] needs to be
assessed in clinical medicine to detect relapses early and
tailor immunosuppressive therapy accordingly. Together,
comprehensive maintenance immunosuppressive therapy,
monitoring of (emerging) vasculitis markers and deter-
mination of T-helper lymphocyte count may help guide
GPA therapy to avoid relapses (Scylla) and over-
immunosuppression (Charybdis).
Consent
Written informed consent for publication of this Case
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